Prognostic Value of [18F]-Fluoromethylcholine Positron Emission Tomography/Computed Tomography Before Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer

Journal Article · Fri Jun 15 04:00:00 EDT 2018 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/J.IJROBP.2018.02.005· OSTI ID:23065585

Cysouw, Matthijs ^[1]; Bouman-Wammes, Esther ^[2]; Hoekstra, Otto ^[1]; Eertwegh van den, Alfons ^[2]; Piet, Maartje ^[3]; Moorselaar, Jeroen van ^[4]; Boellaard, Ronald ^[1]; Dahele, Max ^[3]; Oprea-Lager, Daniela ^[1]

---

1. Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam (Netherlands)
2. Department of Medical Oncology, VU University Medical Center, Amsterdam (Netherlands)
3. Department of Radiation Oncology, VU University Medical Center, Amsterdam (Netherlands)
4. Department of Urology, VU University Medical Center, Amsterdam (Netherlands)

To investigate the predictive value of [{sup 18}F]-fluoromethylcholine positron emission tomography/computed tomography (PET/CT)-derived parameters on progression-free survival (PFS) in oligometastatic prostate cancer patients treated with stereotactic body radiation therapy (SBRT).

• OSTI ID: 23065585
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 2 Vol. 101; ISSN IOBPD3; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
FLUORINE 18
NEOPLASMS
PATIENTS
POSITRON COMPUTED TOMOGRAPHY
PROSTATE
RADIOTHERAPY